<DOC>
	<DOCNO>NCT01500642</DOCNO>
	<brief_summary>The dose mode administration sublingual therapy remain open question determine efficacy safety desensitization therapy , main purpose study evaluate different route administration ( oral-vestibular vs. sublingual ) maximum dose allergen administer able determine different effect different incidence side effect therapy group patient rhinoconjunctivitis and/or asthma due ragweed</brief_summary>
	<brief_title>Comparison Efficacy Safety Different Schedules Administration Sub-lingual Immunotherapy</brief_title>
	<detailed_description>Version 1 16/02/2011 The allergen-specific immunotherapy represent important therapeutic option treatment allergic respiratory disease . Its clinical efficacy well demonstrate , although mechanism action still study . The main purpose immunotherapy induce allergen-specific tolerance natural exposure allergen cause clinical symptom . The clinical efficacy standard subcutaneous immunotherapy ( SCIT ) know . A meta-analysis Cochrane clinical efficacy SCIT allergic rhinitis 51 double-blind study total 2871 patient ) demonstrate reduction symptom 73 % patient reduction use drug 57 % . Other study also show SCIT effective long term ( least 3-5 year suspension ) reduce sensitization new allergen , prevents progression allergic rhinitis asthma significantly improve symptom asthma , hyper- bronchial reactivity use asthma medication . Sublingual immunotherapy ( SLIT ) represent effective alternative route administration vaccine therapy allergic profile security SCIT .</detailed_description>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<criteria>Adults age 1855 year Known allergy ragweed pollen No immunotherapy progress prior enrollment Symptoms rhino / conjunctivitis without asthma Allergic perennial allergen ( mould , mite animal expose animal ) Patients chronic disease ( infectious , autoimmune cancer , heart kidney ) Are pregnant Chronic drug treatment steroid / immunosuppressive Oral disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>